Anticancer Effects of Pimavanserin, a Known Anti-Parkinson Drug

Technology #d-1409

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Sanjay Srivastava
Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Amarillo, Texas
Sharavan Ramachandra
Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas
Managed By
Cameron Smith
Licensing Associate 806-834-6822
Patent Protection

Provisional Patent Application Filed

Cancer treatment methods must meet rigorous constraints before being approved by the FDA for administration to patients. Consequently, it is estimated that in 2012, more than 50% of the diagnosed cancer cases died worldwide due to these constraints preventing usage and treatment. It is becoming increasingly important to present more options for cancer treatment, and improve on existing methods to increase the likelihood of FDA acceptance.  

Taking advantage of an FDA-approved substance, this technology led to 75% suppression in tumor growth in an orthotopic pancreatic cancer model. Pending analysis includes testing the anti-metastasis effects of this technology in the animal models.  

Reference Number: D-1409 

Market Applications: 

  • Cancer Treatment
  • Oncology Research 

Features, Benefits, & Advantages: 

  • Repurposes an existing drug
  • Capable of crossing the blood-brain barrier
  • Limited known side effects 

Intellectual Property: 

  • A US provisional patent, serial number 62585080, was filed on 11/13/17. 

Development Stage: The method has been developed and tested in animal models. 

Researchers:

  • Sanjay Srivastava, Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Amarillo, Texas
  • Sharavan Ramachandra, Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas 

Keywords: Cancer, anticancer, antipsychotic